Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bayer Invests In China R&D Center

by Patricia L. Short
February 16, 2009 | A version of this story appeared in Volume 87, Issue 7

Bayer Schering Pharma will invest nearly $130 million in a new R&D center in Beijing over the next five years. "We are continuously increasing our presence in the Asia-Pacific region, where China is our key growth driver," company Chairman Andreas Fibig says. "In our new R&D center in Beijing, we will establish a world-class R&D team, extending our global R&D expertise and capabilities." China is the third-largest market worldwide for Bayer, and it will become the third country, after Germany and the U.S., to host a global R&D center for Bayer's pharma operations. Bayer also is in advanced discussions with Tsinghua University to establish a partnership focused on discovery of new disease targets.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.